Wyeth Minnesota hormone law suit dismissed

5 November 2007

US pharmaceutical major Wyeth says that the judge in the Hennepin County District Court in Minneapolis, Minnesota has granted the firm's motion for summary judgment on all claims and dismissed the case of Patricia Zandi versus Wyeth, which was scheduled for trial on January 28, 2008. In rulings on the admissibility of plaintiff's expert testimony and on the motion for summary judgment, the court found that the plaintiff had not offered any scientifically valid evidence to support her claim that she developed breast cancer as a result of her use of the hormone replacement agents Premarina and Premproa.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK









Company Spotlight